Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REJOICE-Ovarian 04 phase 3 maintenance study of raludotatug deruxtecan with or without bevacizumab versus standard of care in newly diagnosed advanced non-HRD-positive ovarian cancer
jRCT2020260047Phase 3Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Arm 1: R-DXd with or without bevacizumab with Arm 2: Standard of care (bevacizumab or observation only) (2 arms). Primary endpoints: Progression-Free Survival and Overall Survival. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
raludotatug deruxtecan
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on jRCT2020260047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2020260047.